These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

522 related articles for article (PubMed ID: 30734234)

  • 21. Tofacitinib, the First Oral Janus Kinase Inhibitor Approved for Adult Ulcerative Colitis.
    Palasik BN; Wang H
    J Pharm Pract; 2021 Dec; 34(6):913-921. PubMed ID: 32873116
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis.
    Sandborn WJ; Ghosh S; Panes J; Vranic I; Su C; Rousell S; Niezychowski W;
    N Engl J Med; 2012 Aug; 367(7):616-24. PubMed ID: 22894574
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tofacitinib in the treatment of moderate to severe ulcerative colitis in Colombia: Real world experience.
    Parra-Izquierdo V; Frías-Ordoñez JS; Márquez JR; Juliao-Baños F; Galindo P; Cuadros C; Rojas C; Rojas N; Ardila O; Tovar-Fierro G; García-Duperly R; Vargas M; Flórez-Sarmiento C
    Gastroenterol Hepatol; 2023; 46(7):512-521. PubMed ID: 36372256
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tofacitinib for induction and maintenance therapy of Crohn's disease: results of two phase IIb randomised placebo-controlled trials.
    Panés J; Sandborn WJ; Schreiber S; Sands BE; Vermeire S; D'Haens G; Panaccione R; Higgins PDR; Colombel JF; Feagan BG; Chan G; Moscariello M; Wang W; Niezychowski W; Marren A; Healey P; Maller E
    Gut; 2017 Jun; 66(6):1049-1059. PubMed ID: 28209624
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tofacitinib for the Treatment of Ulcerative Colitis: Analysis of Infection Rates from the Ulcerative Colitis Clinical Programme.
    Winthrop KL; Loftus EV; Baumgart DC; Reinisch W; Nduaka CI; Lawendy N; Chan G; Mundayat R; Friedman GS; Salese L; Thorpe AJ; Su C
    J Crohns Colitis; 2021 Jun; 15(6):914-929. PubMed ID: 33245746
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Real-world clinical and endoscopic outcomes after one year tofacitinib treatment in ulcerative colitis.
    Straatmijer T; van Gennep S; Duijvestein M; Ponsioen CIJ; Gecse KB; D'Haens GR; Löwenberg M
    Eur J Gastroenterol Hepatol; 2021 Oct; 33(10):1288-1297. PubMed ID: 33405424
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and safety of biologic agents and tofacitinib in moderate-to-severe ulcerative colitis: A systematic overview of meta-analyses.
    Pantavou K; Yiallourou AI; Piovani D; Evripidou D; Danese S; Peyrin-Biroulet L; Bonovas S; Nikolopoulos GK
    United European Gastroenterol J; 2019 Dec; 7(10):1285-1303. PubMed ID: 31839954
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tofacitinib Therapy in Children and Young Adults With Pediatric-onset Medically Refractory Inflammatory Bowel Disease.
    Moore H; Dubes L; Fusillo S; Baldassano R; Stein R
    J Pediatr Gastroenterol Nutr; 2021 Sep; 73(3):e57-e62. PubMed ID: 34091545
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Inhibitors of the Janus Kinases: A New Oral Treatment Option for Ulcerative Colitis.
    Antonelli E; Torti G; Bassotti G
    J Clin Gastroenterol; 2019 Oct; 53(9):635-640. PubMed ID: 31373941
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tofacitinib, an Oral Janus Kinase Inhibitor: Analysis of Malignancy (Excluding Nonmelanoma Skin Cancer) Events Across the Ulcerative Colitis Clinical Program.
    Lichtenstein GR; Rogler G; Ciorba MA; Su C; Chan G; Pedersen RD; Lawendy N; Quirk D; Nduaka CI; Thorpe AJ; Panés J
    Inflamm Bowel Dis; 2021 May; 27(6):816-825. PubMed ID: 32766762
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tofacitinib for ulcerative colitis: results of the prospective Dutch Initiative on Crohn and Colitis (ICC) registry.
    Biemans VBC; Sleutjes JAM; de Vries AC; Bodelier AGL; Dijkstra G; Oldenburg B; Löwenberg M; van Bodegraven AA; van der Meulen-de Jong AE; de Boer NKH; Srivastava N; West RL; Römkens TEH; Horjus Talabur Horje CS; Jansen JM; van der Woude CJ; Hoekstra J; Weersma RK; van Schaik FDM; Hoentjen F; Pierik MJ;
    Aliment Pharmacol Ther; 2020 May; 51(9):880-888. PubMed ID: 32237087
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Randomized trial of tofacitinib in active ulcerative colitis: analysis of efficacy based on patient-reported outcomes.
    Panés J; Su C; Bushmakin AG; Cappelleri JC; Mamolo C; Healey P
    BMC Gastroenterol; 2015 Feb; 15():14. PubMed ID: 25651782
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tofacitinib real-world experience in ulcerative colitis in Finland (FinTofUC): a retrospective non-interventional multicenter patient chart data study.
    Molander P; Kosunen M; Eronen H; Tillonen J; Käräjämäki A; Heikkinen M; Punkkinen J; Mattila R; Toppila I; Hölsä O; Kalpala K; Henrohn D; Af Björkesten CG
    Scand J Gastroenterol; 2024 Apr; 59(4):425-432. PubMed ID: 38156792
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Adverse drug events associated with 5mg versus 10mg Tofacitinib (Janus kinase inhibitor) twice daily for the treatment of autoimmune diseases: A systematic review and meta-analysis of randomized controlled trials.
    Huang F; Luo ZC
    Clin Rheumatol; 2019 Feb; 38(2):523-534. PubMed ID: 30242639
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Safety of tofacitinib in IBD: A tricky puzzle.
    Beaugerie L
    United European Gastroenterol J; 2024 Jul; 12(6):658-659. PubMed ID: 38761370
    [No Abstract]   [Full Text] [Related]  

  • 36. Histological Outcomes and JAK-STAT Signalling in Ulcerative Colitis Patients Treated with Tofacitinib.
    van Gennep S; Fung ICN; Jong DC; Ramkisoen RK; Clasquin E; de Jong J; de Vries LCS; de Jonge WJ; Gecse KB; Löwenberg M; Woolcott JC; Mookhoek A; D'Haens GR
    J Crohns Colitis; 2024 Aug; 18(8):1283-1291. PubMed ID: 38506097
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Safety of Tofacitinib in a Real-World Cohort of Patients With Ulcerative Colitis.
    Deepak P; Alayo QA; Khatiwada A; Lin B; Fenster M; Dimopoulos C; Bader G; Weisshof R; Jacobs M; Gutierrez A; Ciorba MA; Christophi GP; Patel A; Hirten RP; Colombel JF; Rubin DT; Ha C; Beniwal-Patel P; Ungaro RC; Syal G; Pekow J; Cohen BL; Yarur A
    Clin Gastroenterol Hepatol; 2021 Aug; 19(8):1592-1601.e3. PubMed ID: 32629130
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparative of the Effectiveness and Safety of Biological Agents, Tofacitinib, and Fecal Microbiota Transplantation in Ulcerative Colitis: Systematic Review and Network Meta-Analysis.
    Zhou HY; Guo B; Lufumpa E; Li XM; Chen LH; Meng X; Li BZ
    Immunol Invest; 2021 May; 50(4):323-337. PubMed ID: 32009472
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Real-World Experience With Tofacitinib Dose De-Escalation in Patients With Moderate and Severe Ulcerative Colitis.
    Yu A; Ha NB; Shi B; Cheng YW; Mahadevan U; Beck KR
    Clin Gastroenterol Hepatol; 2023 Nov; 21(12):3115-3124.e3. PubMed ID: 37187323
    [TBL] [Abstract][Full Text] [Related]  

  • 40. 1-Year Comparative Effectiveness of Tofacitinib vs Ustekinumab for Patients With Ulcerative Colitis and Prior Antitumor Necrosis Factor Failure.
    Dalal RS; Sharma PP; Bains K; Pruce JC; Allegretti JR
    Inflamm Bowel Dis; 2024 Mar; 30(3):395-401. PubMed ID: 37209416
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 27.